Ocrelizumab extended‐interval dosing in multiple sclerosis during <scp>SARS‐CoV</scp>‐2 pandemic: a real‐world experienceSimone Guerrieri, Chiara Bucca, Agostino Nozzolillo et al.|European Journal of Neurology|2023Cited by 29
Machine learning-driven diagnosis of multiple sclerosis from whole blood transcriptomicsMaryam Omrani, Cinthia Farina, Federico Montini et al.|Brain Behavior and Immunity|2024Cited by 14
Effectiveness and safety of monthly versus quarterly fremanezumab for migraine prevention: An Italian, multicenter, real‐life studyLaura Zanandrea, Massimo Filippi, Roberta Messina et al.|European Journal of Neurology|2024Cited by 5